(Symbicort SMARTTM, Turbuhaler®) 160/4.5 μg twice daily plus as needed with similar or higher maintenance doses of ICS/LABA plus SABA or formoterol.	higher maintenance doses of ICS/LABA plus SABA or formoterol	risk of episodes of high reliever use	14460	14651	In both studies the risk of any episode with >6 inhalations/day of reliever was reduced with budesonide/formoterol maintenance and reliever therapy vs. comparators (P ≤ 0.014; Table 2 and 3).
budesonide/formoterol regimens	fixed-dose salmeterol/fluticasone	The risk of hospitalisation/ER visits	23775	23982	The risk of hospitalisation/ER visits in Study B during the 21-day period was significantly (P < 0.05) lower for both budesonide/formoterol regimens compared with fixed-dose salmeterol/fluticasone (Table 3).
(Symbicort SMARTTM, Turbuhaler®) 160/4.5 μg twice daily plus as needed with similar or higher maintenance doses of ICS/LABA plus SABA or formoterol.	higher maintenance doses of ICS/LABA plus SABA or formoterol	risk of episodes of high reliever use	1456	1634	Budesonide/formoterol maintenance and reliever therapy significantly reduced the risk of episodes of high reliever use (>6 inhalations/day) vs. all alternative ICS/LABA regimens.
budesonide/formoterol regimens	fixed-dose salmeterol/fluticasone	The risk of hospitalisation/ER visits	23775	23971	The risk of hospitalisation/ER visits in Study B during the 21-day period was significantly (P < 0.05) lower for both budesonide/formoterol regimens compared with fixed-dose salmeterol/fluticasone
